Covid infection.ZRC-3308 is a cocktail of 2 anti-SARS-CoV-2 monoclonal antibodies.''Zydus Cadila today announced that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19.
SARS-CoV-2 spike protein targeted, neutralizing monoclonal antibody based treatments have received emergency use authorization in mild COVID 19 in the US, Europe and in India because they significantly reduced viral load in mild patients and their rate of hospitalization,'' Cadila Healthcare said in an exchange filing.Zydus is the only Indian company to have developed a neutralizing monoclonal antibody based cocktail for the treatment of COVID-19, it said.